Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases

Mehta, M; Deeksha; Tewari, D; Gupta, G; Awasthi, R; Singh, H; Pandey, P; Chellappan, DK; Wadhwa, R; Collet, T; Hansbro, PM; Kumar, SR; Thangavelu, L; Negi, P; Dua, K; Satija, S

Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases

Mehta, M Deeksha Tewari, D Gupta, G Awasthi, R Singh, H Pandey, P Chellappan, DK Wadhwa, R Collet, T Hansbro, PM

Kumar, SR Thangavelu, L Negi, P Dua, K

Satija, S

Permalink

Publication Type:: Journal Article
Citation:: Chemico-Biological Interactions, 2019, 308 pp. 206 - 215
Issue Date:: 2019-08-01

Closed Access

	Filename	Description	Size
	1-s2.0-S0009279719305757-main.pdf	Published Version	480.41 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Mehta, M	en_US
dc.contributor.author	Deeksha	en_US
dc.contributor.author	Tewari, D	en_US
dc.contributor.author	Gupta, G	en_US
dc.contributor.author	Awasthi, R	en_US
dc.contributor.author	Singh, H	en_US
dc.contributor.author	Pandey, P	en_US
dc.contributor.author	Chellappan, DK	en_US
dc.contributor.author	Wadhwa, R	en_US
dc.contributor.author	Collet, T	en_US
dc.contributor.author	Hansbro, PM https://orcid.org/0000-0002-4741-3035	en_US
dc.contributor.author	Kumar, SR	en_US
dc.contributor.author	Thangavelu, L	en_US
dc.contributor.author	Negi, P	en_US
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159	en_US
dc.contributor.author	Satija, S	en_US
dc.date.available	2019-05-15	en_US
dc.date.issued	2019-08-01	en_US
dc.identifier.citation	Chemico-Biological Interactions, 2019, 308 pp. 206 - 215	en_US
dc.identifier.issn	0009-2797	en_US
dc.identifier.uri	http://hdl.handle.net/10453/136182
dc.description.abstract	© 2019 Elsevier B.V. Oligonucleotide-based therapies are advanced novel interventions used in the management of various respiratory diseases such as asthma and Chronic Obstructive Pulmonary Disease (COPD). These agents primarily act by gene silencing or RNA interference. Better methodologies and techniques are the need of the hour that can deliver these agents to tissues and cells in a target specific manner by which their maximum potential can be reached in the management of chronic inflammatory diseases. Nanoparticles play an important role in the target-specific delivery of drugs. In addition, oligonucleotides also are extensively used for gene transfer in the form of polymeric, liposomal and inorganic carrier materials. Therefore, the current review focuses on various novel dosage forms like nanoparticles, liposomes that can be used efficiently for the delivery of various oligonucleotides such as siRNA and miRNA. We also discuss the future perspectives and targets for oligonucleotides in the management of respiratory diseases.	en_US
dc.relation.ispartof	Chemico-Biological Interactions	en_US
dc.relation.isbasedon	10.1016/j.cbi.2019.05.028	en_US
dc.subject.classification	Toxicology	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Pulmonary Disease, Chronic Obstructive	en_US
dc.subject.mesh	Oligonucleotides, Antisense	en_US
dc.subject.mesh	MicroRNAs	en_US
dc.subject.mesh	RNA, Small Interfering	en_US
dc.subject.mesh	Liposomes	en_US
dc.subject.mesh	Drug Carriers	en_US
dc.subject.mesh	RNA Interference	en_US
dc.subject.mesh	Dendrimers	en_US
dc.subject.mesh	Nanoparticles	en_US
dc.title	Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases	en_US
dc.type	Journal Article
utslib.citation.volume	308	en_US
utslib.for	1102 Cardiorespiratory Medicine and Haematology	en_US
utslib.for	0604 Genetics	en_US
utslib.for	0601 Biochemistry and Cell Biology	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Students
utslib.copyright.status	closed_access
pubs.publication-status	Published	en_US
pubs.volume	308	en_US

Abstract:

© 2019 Elsevier B.V. Oligonucleotide-based therapies are advanced novel interventions used in the management of various respiratory diseases such as asthma and Chronic Obstructive Pulmonary Disease (COPD). These agents primarily act by gene silencing or RNA interference. Better methodologies and techniques are the need of the hour that can deliver these agents to tissues and cells in a target specific manner by which their maximum potential can be reached in the management of chronic inflammatory diseases. Nanoparticles play an important role in the target-specific delivery of drugs. In addition, oligonucleotides also are extensively used for gene transfer in the form of polymeric, liposomal and inorganic carrier materials. Therefore, the current review focuses on various novel dosage forms like nanoparticles, liposomes that can be used efficiently for the delivery of various oligonucleotides such as siRNA and miRNA. We also discuss the future perspectives and targets for oligonucleotides in the management of respiratory diseases.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/136182